摘要
Angiogenesis is considered a hallmark pathophysiological process in tumor development. Aberrant vasculature resulting from tumor angiogenesis plays a critical role in the development of resistance to breast cancer treatments, via exacerbation of tumor hypoxia, decreased effective drug concentrations within tumors, and immune-related mechanisms. Antiangiogenic therapy can counteract these breast cancer resistance factors by promoting tumor vascular normalization. The combination of antiangiogenic therapy with chemotherapy, targeted therapy, or immunotherapy has emerged as a promising approach for overcoming drug resistance in breast cancer. This review examines the mechanisms associated with angiogenesis and the interactions among tumor angiogenesis, the hypoxic tumor microenvironment, drug distribution, and immune mechanisms in breast cancer. Furthermore, this review provides a comprehensive summary of specific antiangiogenic drugs, and relevant studies assessing the reversal of drug resistance in breast cancer. The potential mechanisms underlying these interventions are discussed, and prospects for the clinical application of antiangiogenic therapy to overcome breast cancer treatment resistance are highlighted.
基金
supported by the National Natural Science Foundation of China (Grant No. 81973861)
Zhejiang Provincial Ministry Medical and Health Co-construction Major Project (Grant No. 20214355173)
Zhejiang Science and Technology Department“Vanguard”“Leading Goose”research (Grant No. 2023C03044)
Zhejiang Provincial Health“Leading Talents”Project
Zhejiang Medical and Health Science and Technology Project (Grant No. 2022KY558)。
